Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | CNR2 | P34972 | 4/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28319350 | 0.86 | GSK3B (0.45) | PTGS1PTGS2GSK3BKCNA5CNR1 | |
| SCHEMBL17077541 | 0.85 | PDCD1 (0.50) | GSK3BCNR1CNR2GPR139PSEN1 | |
| SCHEMBL1565662 | 0.84 | GRM4 (0.45) | GSK3BKCNA5CNR1CNR2GPR139 | |
| SCHEMBL20560710 | 0.84 | PTGS1 (0.56) | PTGS1PTGS2MT-CO2KMT2A | |
| SCHEMBL1565661 | 0.84 | GRM4 (0.45) | GSK3BKCNA5CNR1CNR2GPR139 | |
| SCHEMBL14660829 | 0.83 | GSK3B (0.42) | GSK3BKCNA5CNR1CNR2GPR139 | |
| SCHEMBL7116483 | 0.83 | GSK3B (0.49) | GSK3BKCNA5CNR1CNR2GPR139 | |
| SCHEMBL6933729 | 0.82 | MGLL (0.43) | GSK3BKCNA5CNR1ADRA1DADRA2B | |
| SCHEMBL28122440 | 0.82 | MGLL (0.50) | PTGS1PTGS2GSK3BKCNA5CNR1 | |
| SCHEMBL1990381 | 0.82 | PTGS1 (0.54) | PTGS1PTGS2GSK3BCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-115340555-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2021227906-A1 | PYRIDINE ACETAMIDE DERIVATIVE SERVING AS CDK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| CN-113173924-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| EP-2760835-A1 | ARYL OR N-HETEROARYL SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2760836-A1 | AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045447-A1 | ARYL OR N-HETEROARYL SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079377-A1 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079377-A1 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079377-A1 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079377-A1 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | TRPV1, TRPV3, TRPA1 | PTGS1 710/4885PTGS2 772/4885GSK3B 3839/4885 |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | TRPV1, TRPA1, TRPV3 | PTGS1 536/4885PTGS2 629/4885GSK3B 3046/4885 |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | PTGS1 1205/4885PTGS2 2365/4885GSK3B 1207/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | PTGS1 268/4885PTGS2 524/4885GSK3B 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.